NYSEHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading PHR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a long-term investment in a company with robust earnings quality and strong recent financial performance. However, it carries high risk due to potential market volatility and an expensive valuation compared to peers.
The market currently assumes a justified valuation, with a premium compared to peers. There is an expectations gap indicating that some positive performance is already priced in, but the stock's fragility remains low.
Management is focused on achieving revenue growth targets for FY 2027, which shows progress. However, the mixed status of adjusted EBITDA and restructuring efforts suggests some uncertainty in execution.
The thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM. If these companies continue to perform well, it could support PHR's growth. Conversely, any negative guidance from these peers could impact PHR's momentum.
Overall, PHR's multi-year view remains intact, but investors should be cautious of potential risks. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent legal issues may impact investor confidence and operations. Class action lawsuits could distract management from focusing on growth.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or exceeding this target shows progress toward the $510M-$520M goal for FY 2027.
Confirms:Q2 revenue reported at or above $130M.
Disproves:Q2 revenue reported below $130M.
Why it matters: Confirming the revenue target of $510M-$520M shows strong growth momentum. It reassures investors about the company's future.
Confirms:Management confirms revenue growth in the next earnings call on September 3, 2026.
Disproves:Management lowers the revenue guidance below $510M for FY 2027.
Why it matters: Revenue guidance of $510M-$520M indicates growth expectations. Confirmation shows the company is on track.
Confirms:Fiscal 2027 revenue reported within the range of $510M-$520M.
Disproves:Fiscal 2027 revenue reported below $510M.
Why it matters: If revenue growth picks up, it could indicate a positive shift for Phreesia's market.
Confirms:3-year revenue growth in the health care sector rises above 12 percent.
Disproves:3-year revenue growth in the health care sector stays below 10 percent.
Why it matters: The adjusted EBITDA target of $125M-$135M is crucial for growth. Meeting this target signals strong operational performance.
Confirms:Adjusted EBITDA for Q2 exceeds $135M.
Disproves:Adjusted EBITDA for Q2 falls below $125M.
Why it matters: Adjusted EBITDA target of $125M-$135M is key for profitability. Results will show financial health.
Confirms:Adjusted EBITDA reported within the range of $125M-$135M.
Disproves:Adjusted EBITDA was below $125M.
